Literatür Detay Bilgisi
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B-cell lymphoma: a nationwide retrospective study

Yazarlar : Chihara D, Izutsu K, Kondo E et al

Yayın : Biol Blood Marrow Transplant

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/high-dose-chemotherapy-autologous-stem-cell-transplantation-elderly-patients-relapsed-refractory-dif?tsid=5

Konu : Geriyatrik Hematoloji

Literatür İçeriği :  The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) continues to increase but the data of autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients aged 60 years or over diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64 years (range: 60-78). To evaluate the impact of age at ASCT, patients were classified into three groups those aged 60 to 64, 65 to 69, and 70 years or over. Overall non-relapse mortality (NRM) at day 100, one year and two years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (p = 0.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients aged 60-64, however, survival rate was acceptable even in those aged 70 or over with a two-year OS of 46%. ASCT is feasible in selected elderly patients and age alone would not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.


Literatür Arşivi

Konusu Aynı Olan Diğer Materyaller
SunumlarVideolarOlgu Tartışması